LXEO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
28.0M
+25.5%
22.3M
-3.4%
23.1M
+6.8%
21.6M
-29.5%
30.7M
R&D
19.0M
+21.2%
15.7M
-3.1%
16.2M
+3.3%
15.7M
+6.6%
14.7M
SG&A
9.0M
+35.6%
6.6M
-4.0%
6.9M
+16.0%
6.0M
-62.7%
16.0M
Operating Income
-28020000
-25.5%
-22333000
+3.4%
-23116000
-6.8%
-21648000
+29.5%
-30688000
EBITDA
-27946000
-25.5%
-22260000
+3.4%
-23043000
-6.0%
-21735000
+29.0%
-30626000
Net Income
-25867000
-28.1%
-20196000
+3.5%
-20919000
-3.1%
-20283000
+22.3%
-26103000
EPS (Basic)
$-0.30
-20.0%
$-0.25
+7.4%
$-0.27
+18.2%
$-0.33
+45.0%
$-0.60
EPS (Diluted)
$-0.30
-20.0%
$-0.25
+7.4%
$-0.27
+18.2%
$-0.33
+45.0%
$-0.60
Shares (Diluted)
85.6M
+5.5%
81.2M
+5.6%
76.9M
+26.1%
61.0M
+39.9%
43.6M
Lexeo Therapeutics (LXEO) โ€” Financials